A novel butyrolactone derivative inhibited apoptosis and depressed integrin beta4 expression in vascular endothelial cells

Bioorg Med Chem Lett. 2007 Jan 15;17(2):482-5. doi: 10.1016/j.bmcl.2006.10.023. Epub 2006 Oct 12.

Abstract

To understand the effects of a novel butyrolactone derivative, 3-benzyl-5-((2-nitrophenoxy) methyl)-dihydrofuran-2(3H)-one (3BDO), on the apoptosis of vascular endothelial cells (VECs), we exposed 3BDO (20-60 microg/ml) to VECs deprived of serum and FGF-2 for 24 and 48 h, respectively. The results showed that 3BDO (20-60 microg/ml) increased VEC viability and inhibited VEC apoptosis induced by deprivation of serum and FGF-2 in a very weak dose-dependent manner. During this process, integrin beta4 expression was depressed, but the level of reactive oxygen species (ROS) was not changed. The data suggested that 3BDO (20-60 microg/ml) could inhibit VEC apoptosis and suppress integrin beta4 expression, but it could not depress the ROS level induced by deprivation of serum and FGF-2.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • 4-Butyrolactone / analogs & derivatives*
  • 4-Butyrolactone / chemical synthesis*
  • 4-Butyrolactone / pharmacology*
  • Apoptosis / drug effects*
  • DNA / drug effects
  • DNA Fragmentation / drug effects
  • Endothelial Cells / drug effects
  • Endothelial Cells / metabolism*
  • Endothelium, Vascular / cytology*
  • Endothelium, Vascular / drug effects
  • In Situ Nick-End Labeling
  • Integrin beta4 / biosynthesis*
  • Reactive Oxygen Species / metabolism

Substances

  • Integrin beta4
  • Reactive Oxygen Species
  • DNA
  • 4-Butyrolactone